Allogeneic Hematopoietic Stem Cell Transplantation for Multiple Myeloma

Inclusion Criteria: * Diagnosis of multiple myeloma * Have a suitable related or unrelated donor * Age ≥18 but \<70 yrs * KPS of ≥70% * Recovery from complications of previous therapies Exclusion Criteria: * Diagnosis other than multiple myeloma * Chemotherapy or radiotherapy within 21 days of initiating treatment in this study * Prior dose-intense therapy requiring HSC support within 56 days of initiating treatment in this study * Uncontrolled bacterial, viral, fungal or parasitic infections * Uncontrolled CNS metastases * Known amyloid deposition in heart * Organ dysfunction * LVEF \<40% or cardiac failure not responsive to therapy * FVC, FEV1, or DLCO \<50% of predicted and/or receiving supplementary continuous oxygen * Evidence of hepatic synthetic dysfunction, or total bilirubin \>2x or AST \>3x ULN * Measured creatinine clearance \<20 ml/min * Sensory peripheral neuropathy grade 4 within 14 days of enrollment * Karnofsky score \<70% unless a result of bone disease directly caused by myeloma * Life expectancy limited by another co-morbid illness * Diagnosed or treated for another malignancy within 3 years of enrollment, with the exception of complete resection of basal cell carcinoma or squamous cell carcinoma of the skin, an in situ malignancy, or low-risk prostate cancer after curative therapy * Female subject is pregnant or breast-feeding (women) or unwilling to use acceptable birth control methods (men or women) for twelve months after treatment. Confirmation that…